the UK intellectual property investment group that invests in university technology, told investors on Monday that its portfolio company, Salarius, has secured a new order for its MicroSalt®.
MicroSalt® is a proprietary salt made with micron-size salt particles that dissolve in the mouth significantly faster than regular salt, delivering an increased sensation of saltiness with much less salt, resulting in approximately 50% less sodium.
Victor Hugo Manzanilla, CEO of Salarius said: “Salarius is in discussions with numerous snack food companies who are evaluating MicroSalt® for possible inclusion in their products, and we will update the market in due course,"
Shares in Tekcapital were trading 6.98% higher at 11.5p each following the news
The company said the order came from a Mexican seafood company for use in dried shrimp snacks.
Dr Clifford Gross, Executive Chairman at Tekcapital, commented: "We are delighted with Salarius' continued progress. MicroSalt® has the potential to help companies and consumers worldwide enjoy full-flavour snacks with reduced sodium."
Interestingly, the National Academies of Sciences, Engineering, and Medicine recently recommended significantly reduced sodium consumption guidelines because of the fact that high blood pressure is a key risk factor for heart disease.
Salarius' MicroSalt® is targeting food companies and consumers to meet these new potential guidelines.
Healthy option products are gaining significant market traction with both consumers and investors, as seen by the highly popular IPO of Beyond Meat (BYND) in the US.
The Nasdaq listed company offers plant-based meats offers a similar taste profile to meat but is healthier for both consumers and the environment.
Tekcapital highlighted that the global savory snacks market is expected to reach US$108 billion by 2021, and that the low sodium ingredient market is estimated to reach US$1.76 billion by 2025.
"Both markets could immediately benefit from the availability of MicroSalt®.” CEO Victor Manzanilla said.
Follow News & Updates from Tekcapital here:
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
SP Angel research note on commodities and miners, featuring: Ferro-Alloy Resources Limited (FAR LN) – Fall in vanadium pentoxide price prompts management to look for new funding Resolute Mining (RSG LN) – Bibiani review Sirius Minerals (SXX LN) – A Siriusly sorry Christmas Carol Vast Resources* (VAST LN) 0.29p, Mkt Cap £29m – Exposure to copper and rough diamonds in Romania and Zimbabwe
Colin Bird Executive Chairman of Xtract Resources (XTR) talks about the Alluvial Collaboration Agreement with Nexus and provides a general update Russ Mould, Investment Director at stockbroker AJ Bell talks about: the Election Result, Macro and UK stocks Alan Green talks about 4 stocks
Mammoth Biosciences is a US-based biotech company that developed the world's first CRISPR-based detection platform capable of sensing any biomarker or disease with DNA/RNA backed by investors that include Mayfield, NFX, 8VC, AME Cloud, Wireframe, Kairos, along with Tim Cook, Brook Byers, Bob Nelsen, and Jeff Huber.
“It has given us substantial financial flexibility at a highly competitive rate of interest in the last three years as we have successfully carried out our multi-well Niger drilling campaign and completed the Seven Energy transaction."
Tim McCarthy, Chairman of ImmuPharma (IMM) discusses the deal with US-based Avion Pharmaceuticals, the agreement with Lanstead Capital and what the future holds for ImmuPharma regarding new trial design as well as anticipated upcoming milestones.
The hedge fund owned by the billionaire investor and anti-Brexit donor George Soros has made a £16m bet against shares in the owner of the Daily Mail newspaper, Ocado has said its product range will be 50% bigger and offer lower prices and better quality products when it switches from Waitrose to Marks & Spencer next year,
SPAngel research note on commodities and miners, featuring: Base Resources (BSE LN) – Toliara DFS confirms PFS estimates Premier African Minerals* (PREM LN) – Fundraising Resolute Mining (RSG LN) – Drilling results from Tabakoroni